Nekvnro Horse Paste. Pain Relief Patch

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the relief of pain through the application of a horse paste pain relief patch. The patch is designed to provide deep pain relief for a duration of up to 12 hours.

Limitations of Use: The safety and efficacy of this drug have not been established in populations outside of the indicated use.

Dosage and Administration

The affected area should be cleaned and dried prior to application. A single patch should be removed from its film and applied to the affected area. The application of patches should not exceed 3 to 4 times daily, with an interval of 1 to 2 hours between the application of two patches.

For pediatric patients under 12 years of age, it is recommended to consult a physician before use.

Contraindications

Use of this product is contraindicated in the following situations:

• Application on wounds or damaged skin is prohibited due to the risk of exacerbating injury or infection.

• Concurrent use with a heating pad is not recommended, as it may lead to increased skin irritation or burns.

• Individuals with known allergies to any ingredients in this product should avoid its use to prevent allergic reactions.

Additionally, the product should be discontinued if localized skin reactions occur, including rash, itching, redness, irritation, pain, swelling, or blistering. If conditions worsen or symptoms persist for more than 7 days, or if symptoms resolve and then recur within a few days, use should also be stopped. Pregnant or breastfeeding individuals should refrain from using this product due to potential risks to the fetus or infant.

It is essential to use the product only as directed, avoiding contact with the eyes, mucous membranes, or rashes, and not to apply tight bandages. Keep out of reach of children; in the event of ingestion, seek medical assistance or contact a Poison Control Center immediately.

Warnings and Precautions

For external use only. It is imperative to keep this product out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

General precautions must be observed to ensure safe use. This product should not be applied to wounds or damaged skin, nor should it be used in conjunction with a heating pad. Additionally, individuals with known allergies to any of the product's ingredients should refrain from using it.

Healthcare professionals should advise patients to discontinue use and consult a physician if any localized skin reactions occur, including but not limited to rash, itching, redness, irritation, pain, swelling, or blistering. Furthermore, patients should stop using the product if their condition worsens, if symptoms persist beyond 7 days, or if symptoms resolve and then recur within a few days.

Pregnant or breastfeeding individuals are advised against using this product to ensure their safety and that of their child.

Side Effects

Patients using this product may experience localized skin reactions, which can include rash, itching, redness, irritation, pain, swelling, and blistering. These reactions are typically mild but warrant attention. If any of these localized skin reactions occur, patients are advised to stop use and consult a healthcare professional, especially if the condition worsens or if symptoms persist for more than 7 days.

Additionally, patients should seek medical advice if symptoms clear up and then recur within a few days. It is also important to note that this product is for external use only. Pregnant or breastfeeding individuals should refrain from using this product due to potential risks.

Drug Interactions

There are no specific drug interactions reported for this medication. Additionally, no laboratory test interactions have been identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Nekvnro Horse Paste. Pain Relief Patch (horse paste pain relief patch). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should consult a healthcare professional prior to use. It is important to assess the appropriateness of treatment and dosage for this age group, as specific recommendations may vary based on individual health needs and conditions.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should not use this product. The potential risks associated with the use of this medication during pregnancy or lactation have not been established, and its safety profile in these populations remains unclear. Healthcare professionals are advised to consider alternative treatments for women who are pregnant or nursing.

Lactation

Lactating mothers are advised against the use of this product during breastfeeding. There is no available data on the excretion of the product in human milk or its effects on breastfed infants. Therefore, caution is warranted, and alternative treatments should be considered for lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure safety and therapeutic effectiveness.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or toxicology experts for guidance on specific management protocols and interventions tailored to the situation.

Documentation of the incident, including the substance involved, estimated dose, and time of ingestion, is crucial for effective management and treatment.

Nonclinical Toxicology

If pregnant or breastfeeding, the use of this product is contraindicated due to potential teratogenic effects. No information regarding non-teratogenic effects is available. Additionally, there are no details provided concerning animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children. Instruct patients that if the product is swallowed, they should seek medical help or contact a Poison Control Center immediately.

Additionally, it is important to inform patients that this product should not be used during pregnancy or while breastfeeding. Healthcare providers should encourage patients to discuss any concerns or questions regarding the use of this product in these circumstances.

Storage and Handling

The product is supplied in various packaging configurations, with specific NDC numbers available for identification. It is essential to store the product in a cool, dry place, avoiding direct sunlight to maintain its integrity. Additionally, the product must be protected from excessive moisture to ensure optimal quality and efficacy. Proper handling and storage conditions are crucial for preserving the product's effectiveness.

Additional Clinical Information

Patients should apply one patch at a time to the affected area, with a maximum of three to four applications daily, ensuring an interval of 1 to 2 hours between the application of two patches. Clinicians should advise patients that the product is not recommended for use during pregnancy or breastfeeding. Additionally, it is important to keep the product out of reach of children; if ingested, medical assistance or contact with a Poison Control Center should be sought immediately.

Drug Information (PDF)

This file contains official product information for Nekvnro Horse Paste. Pain Relief Patch, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)